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Oral contraceptives combined with
interferon b in multiple sclerosis
ABSTRACT
Objective: To test the effect of oral contraceptives (OCs) in combination with interferon b (IFN-b)
on disease activity in patients with relapsing-remitting multiple sclerosis (RRMS).
Methods: One hundred fifty women with RRMS were randomized in a 1:1:1 ratio to receive IFN-
b-1a subcutaneously (SC) only (group 1), IFN-b-1a SC plus ethinylstradiol 20 mg and desogestrel
150 mg (group 2), or IFN-b-1a SC plus ethinylestradiol 40 mg and desogestrel 125 mg (group 3).
The primary endpoint was the cumulative number of combined unique active (CUA) lesions on
brain MRI at week 96. Secondary endpoints included MRI and clinical and safety measures.
Results: The estimated number of cumulative CUA lesions at week 96 was 0.98 (95% confidence
interval [CI] 0.81–1.14) in group 1, 0.84 (95% CI 0.66–1.02) in group 2, and 0.72 (95% CI
0.53–0.91) in group 3, with a decrease of 14.1% (p 5 0.24) and 26.5% (p 5 0.04) when com-
paring group 1 with groups 2 and 3, respectively. The number of patients with no gadolinium-
enhancing lesions was greater in group 3 than in group 1 (p 5 0.03). No significant differences
were detected in other secondary endpoints. IFN-b or OC discontinuations were equally distrib-
uted across groups.
Conclusions: Our results translate the observations derived from experimental models to patients,
supporting the anti-inflammatory effects of OCs with high-dose estrogens, and suggest possible
directions for future research.
Classification of evidence: This study provides Class II evidence that in women with RRMS, IFN-b
plus ethinylstradiol and desogestrel decreases the cumulative number of active brain MRI lesions
compared with IFN-b alone. Neurol Neuroimmunol Neuroinflamm 2015;2:e120; doi: 10.1212/
NXI.0000000000000120
GLOSSARY
AE 5 adverse event; ARR 5 annualized relapse rate; CI 5 confidence interval; CUA 5 combined unique active; EAE 5
experimental autoimmune encephalomyelitis; EDSS 5 Expanded Disability Status Scale; Gd 5 gadolinium; IFN5 interferon;
IL 5 interleukin; ITT 5 intention to treat; MS 5 multiple sclerosis; OC 5 oral contraceptive; RA 5 rheumatoid arthritis;
RRMS 5 relapsing-remitting MS; SC 5 subcutaneous; tiw 5 3 times a week.
Multiple sclerosis (MS) is an inflammatory disease with a higher prevalence in women, and it
occurs at an average age that overlaps with their childbearing years.1,2
Interferon b (IFN-b) is a widely used treatment for relapsing-remitting MS (RRMS) that is
not associated with an increased risk of spontaneous abortion or fetal complications.3–6 How-
ever, to avoid unexpected pregnancies, clinicians are frequently asked about the risks of oral
contraceptives (OCs) in combination with IFN-b treatment. In the absence of practice guide-
lines, the use of OCs is discussed on an individual basis.
From the Department of Neurology and Psychiatry (C.P., L.D.G., F.D.A., M.C.P., V.T., P.P.), Sapienza University of Rome, Italy; MS Center
(C.P., L.D.G., V.T.B., F.M.), S. Andrea Hospital, Sapienza University of Rome, Italy; Centre for Primary Care and Public Health (V.G.), Queen
Mary University of London, UK; TFS Trial Form Support S.L. (V.A.P., S.M.), Rome, Italy; Institute of Psychological Medicine and Clinical
Neurosciences (V.T.), Cardiff University School of Medicine University Hospital of Wales (V.T.), Cardiff, UK; Santa Lucia Foundation (V.T.),
Rome, Italy; and IRCCS Neuromed (P.P.), Pozzilli (IS), Italy.
Coinvestigators are listed at Neurology.org/nn.
Funding information and disclosures are provided at the end of the article. Go to Neurology.org/nn for full disclosure forms. The Article Processing
Charge was paid by Sapienza University of Rome, CIMS.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC
BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used
commercially.
Neurology.org/nn © 2015 American Academy of Neurology 1
ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Although experimental evidence supports
the anti-inflammatory properties of estrogens
and treatment with high doses of the preg-
nancy hormone estriol has been demonstrated
to ameliorate the course of MS,7–9 whether
OC use influences disease outcome is still a
matter of debate. In patients using OCs, the
onset of MS occurs at an older age10,11 and is
associated with a less disabling course.12 On
the other hand, in progressing-onset MS, a
more rapid disease progression is associated
with the use of OCs.13 Moreover, women
receiving assisted reproduction technology
treatment cycles showed a dramatic increase
in MS disease activity,14 thus contributing to
ambiguous evidence for the effect of sex hor-
mones on MS.
This multicenter, randomized OC combi-
nation trial was designed to test the efficacy
and safety of IFN-b-1a subcutaneous (SC)
combined with OCs on reducing disease activ-
ity in patients with RRMS. Based on clinical
and experimental evidence,15 we hypothesized
that estrogens exert anti-inflammatory effects
in MS and these effects are dose-dependent.
METHODS Patients. Recruitment from 5 MS centers in Italy
started in September 2004, and the last patient visit was in
November 2009. Eligibility criteria included women with RRMS
aged between 18 and 45 years,16 an Expanded Disability Status
Scale (EDSS) score of #5.0, at least 2 relapses in the previous 48
months or one relapse in the preceding 12 months, and no re-
lapses or steroid intake in the previous 60 days. Exclusion criteria
included pathology of the reproductive system, pregnancy or
interruption of pregnancy in the previous 12 months, prior
immunosuppressive therapy, use of IFN-b or any experimental
drugs before study entry, and use of glatiramer acetate and OCs in
the prior 3 months.
Standard protocol approvals, registrations, and patient
consents. This trial was registered with ClinicalTrials.gov
(NCT00151801) and approved by the local ethics committees.
Participants provided written informed consent.
Study design. This was a randomized, controlled, multicenter,
investigator-run 24-month trial of combination therapy. After a
screening phase, eligible patients were randomly assigned in a
1:1:1 ratio to receive IFN-b-1a 44 mg (Rebif; Merck Serono,
Geneva, Switzerland) 3 times a week (tiw) SC (group 1), IFN-
b-1a 44 mg tiw SC plus ethinylestradiol 20 mg and desogestrel
150 mg (Mercilon; MSD Italia SRL, Rome, Italy) (group 2), or
IFN-b-1a 44mg tiw SC plus ethinylestradiol 40mg and desogestrel
125 mg (Gracial; Organon Italia S.p.A., Rome, Italy) (group 3).
The randomization list was generated by a computer with a
dynamic allocation by an independent national research
organization (Istituto Superiore Sanità, Rome, Italy).
Study procedures. A 2-physician (treating and assessing) model
was used to assist with study masking. The treating physician at
each site was responsible for evaluating patient eligibility and
for recording and managing adverse events (AEs). He or she
was not blinded to treatment arm. The assessing physician was
an independent and certified examining neurologist who was
exclusively responsible for all neurologic assessments, beginning
with the screening assessment and the EDSS scoring. He or she
was blinded to treatment arm.
Clinical examinations were performed at baseline and then
every 6 months. On-study relapse was defined as new or recurrent
symptoms lasting for more than 24 hours and developing #30
days after the onset of a previously confirmed exacerbation, in the
absence of fever and with clinically objective changes on the neu-
rologic examination. Relapses were treated with IV methylpred-
nisolone 1 g daily for 3 to 5 consecutive days.
Safety measures included reports of AEs and clinical or labo-
ratory test abnormalities. Interviews at follow-up visits focused on
frequent symptoms attributed to OC use (e.g., migraine, smok-
ing, hypertension, and deep vein thrombosis) and on adherence
to the treatment. Laboratory tests were performed at screening,
at baseline, every 4 weeks for the first 12 weeks, and then every
12 weeks.
Brain MRI scans were performed on 1.5T systems at baseline,
at week 48, and at week 96.
Standard MRI protocol was performed, consisting of 46 con-
tiguous, 3 mm-thick slices obtained in the axial plane before and
5 minutes after IV injection of 0.1 mmol/kg of gadolinium (Gd).
MRIs were sent electronically to the Neuroscience MRI Lab-
oratory of Sapienza University of Rome for analysis. Hyperin-
tense lesion volumes on T2-weighted images and hypointense
lesion volumes on T1-weighted postcontrast images were identi-
fied and quantified using a semi-automated method (Jim 4.0; Xi-
napse Systems, Leicester, UK) requiring the agreement of 2
trained researchers (V.T.B. and M.C.P.) unaware of clinical data.
When there was a disagreement, a third senior neuroradiologist
reviewed the images and a final consensus was reached. On
follow-up images, a lesion was defined as “new” if it did not
overlap with a lesion seen on the previous images by more than
20% for small lesions (volume less than a sphere of 5 mm diam-
eter) or 50% for larger lesions (volume greater than a sphere of 5
mm diameter).
Endpoints. The primary endpoint was the cumulative number
of combined unique active (CUA) lesions at week 96, which were
defined as new nonenhancing T2-weighted lesions or new Gd-
enhancing T1-weighted lesions (without double counting)
(Class II evidence). Secondary MRI endpoints were the
cumulative number of CUA lesions at week 48, the mean
number of new Gd-enhancing lesions per patient per scan at
weeks 48 and 96, the percentage of patients with no Gd-
enhancing lesions at weeks 48 and 96, and the mean change
from baseline in the total volume of T2-hyperintense lesions
and T1-hypointense lesions at week 96 (Class II evidence).
Secondary clinical endpoints were the proportion of relapse-
free patients and the proportion of patients with sustained disabil-
ity progression, defined as a sustained increase (for 6 months) of
at least 1 point in the EDSS score or an increase of at least 1.5
points if the baseline EDSS score was 0 (Class II evidence).
Safety measures. The safety assessments included clinical and
laboratory-based AEs. Laboratory values 2.5-fold below or
above normal limits were considered to be AEs and appropriate
actions were taken. Tolerability was judged based on treatment
discontinuations due to AEs.
Statistical analysis. This study was powered to detect an effect
of OCs in combination with IFN-b treatment on conventional
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MRI markers of inflammation. On the basis of previous data,17
the cumulative number of CUA lesions in group 1 at week 96 was
estimated to be 2, and the relative reduction in the number of
CUA lesions was estimated to be 30% in group 3. Assuming 10%
dropouts, 50 patients per group were required to provide a sta-
tistical power of 80% with a significance level of 0.05.
The primary analyses were performed on the intention-to-
treat (ITT) population, which included all patients treated with
at least 1 dose of IFN-b. To control for type I errors, multiplicity
adjustment was applied to testing for comparisons between
groups in a hierarchical order (first test: group 3 vs group 1;
second test: group 2 vs group 1). Each test was performed at a
significance level of 0.05. The lower-rank testing was considered
for inferential analysis only when higher-rank testing indicated
statistical significance. The primary endpoint was calculated using
a Poisson regression model with effect for study group and adjust-
ment for age, baseline EDSS, and number of Gd-enhancing le-
sions. The cumulative number of CUA lesions at week 48 and the
mean number of new Gd-enhancing lesions per patient per scan
at weeks 48 and 96 were analyzed similarly to the primary end-
point. The percentage of patients with no Gd-enhancing lesions
at weeks 48 and 96 was analyzed using a logistic regression model
with effect for study group and adjustment for baseline number of
Gd-enhancing lesions. Changes in the total volume of T2-
hyperintense lesions and T1-hypointense lesions at week 96 were
measured by analysis of covariance with effect for study group and
adjustment for baseline values. Annualized relapse rate (ARR) was
measured by a negative binomial regression model with effect for
study group and adjustment for age and number of relapses in the
preceding 2 years. A Cox proportional hazards model was used to
calculate the proportion of relapse-free patients and of patients
with sustained progression at week 96, with adjustment for study
group, age, and ARR in the former group and adjustment for
baseline EDSS score in the latter group. Sensitivity analyses were
conducted for an ITT-modified cohort, which consisted of all
patients treated for at least 3 months. All statistical analyses were
performed using SAS 9.1 (SAS Institute, Inc., Cary, NC).
Data management and analyses were performed by an inde-
pendent research organization (TFS Trial Form Support S.L.,
Rome, Italy) with no role in the study design and data collection.
RESULTS Study population. A total of 192 women
were considered eligible for the study. Forty-two
declined to participate or were excluded in the
screening phase, 150 were randomized, and 149
received at least 1 dose of the study drug (ITT
population). Figure 1 shows patient allocation to
the study groups.
A total of 148 patients completed the 96 weeks of
follow-up. Five patients in group 1, 6 patients in
group 2, and 4 patients in group 3 discontinued
IFN-b treatment. Twelve and 13 patients discontin-
ued OCs prematurely in groups 2 and 3, respectively.
Time at which treatment discontinuation occurred
was comparable across groups. The mean (median)
duration of IFN-b therapy was 23.1 (24) months in
group 1, 21.9 (24) months in group 2, and 23.8 (24)
months in group 3. The mean (median) duration of
OC treatment was 20.6 (24) months in group 2 and
19.3 (24) months in group 3. Baseline characteristics
were similar across the study groups (table 1).
Figure 1 Numbers of patients who underwent randomization and completed 96 weeks of follow-up
IFN 5 interferon; ITT 5 intention to treat; OC 5 oral contraceptives.
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Efficacy. The estimated number of cumulative CUA
lesions at week 96 (primary endpoint) was 0.98
(95% confidence interval [CI] 0.81–1.14) in group
1, 0.84 (95% CI 0.66–1.02) in group 2, and 0.72
(95% CI 0.53–0.91) in group 3. This represented a
relative reduction of 14.1% (p 5 0.24) for group 2
and 26.5% (p5 0.04) for group 3 (table 2; figure 2).
Other MRI and clinical endpoints are also shown in
table 2.
Compared with group 1, group 3 showed a rela-
tive reduction of 65.4% in the number of new Gd-
enhancing lesions per patient per scan at week 48
(p 5 0.04). At week 96 there was a trend for signif-
icance (relative reduction 54.2%, p5 0.07). Group 2
showed a nonsignificant relative reduction of 7.4% in
the number of new Gd-enhancing lesions per patient
per scan at week 48 (p 5 0.83), with a trend to sig-
nificance at week 96 (relative reduction 52.4%, p 5
0.07) (figure e-1 at Neurology.org/nn).
A significant increase (p 5 0.03) in the number of
patients with no Gd-enhancing lesions at week 96 was
observed in group 3 compared with group 1 (table 2).
No significant differences across groups were
observed for the other MRI and clinical outcomes
(table 2). No significant differences across groups
were detected in the primary and secondary end-
points using the sensitivity analysis.
Finally, a significant correlation between CUA le-
sions at week 96 and baseline Gd-enhancing lesions
was found in group 1 but not in groups 2 and 3, as
shown in figure e-2.
Safety. All patients followed the prescribed regimen of
the IFN-b treatment. Fifteen patients withdrew from
IFN-b treatment. Reasons for IFN-b withdrawal
were AEs (n 5 5), disease progression (n 5 7), lost
to follow-up (n 5 2), and pregnancy (n 5 1).
The incidence of IFN-b–related AEs was similar
in the 3 groups, except for a slightly lower incidence
of flu-like syndrome in the OC-treated groups than in
group 1 (table e-1). There were no serious AEs. AEs
were of mild or moderate severity in the majority of
patients. OC-related AEs occurred similarly in the 2
OC groups. Only 1 patient in group 2 interrupted
OC treatment following an episode of deep vein
thrombosis (table e-1).
DISCUSSION Our study showed that the anti-
inflammatory effect of treatment, as measured by
MRI activity, was more pronounced in patients
receiving high-dose estrogens than in those
receiving IFN-b alone. Although the study was not
powered to demonstrate a significant reduction in the
relapse rate or in the proportion of patients with
sustained disability progression, we investigated
Table 1 Baseline demographic, disease, and MRI characteristics of the patients
Group 1
(n 5 50), IFN-b
Group 2 (n 5 50), IFN-b 1 OC
with low-dose estrogens
Group 3 (n 5 49), IFN-b 1 OC
with high-dose estrogens
Age, y 29.8 6 7.2 28.9 6 6.8 29.9 6 5.6
Disease duration, y 3.97 6 4.4 3.41 6 3.2 3.44 6 3.9
Annualized relapse rate in the
prior 2 y
0.78 6 0.46 0.74 6 0.34 0.76 6 0.43
No. of women with previous
pregnancies (%)
11 (22) 8 (16) 9 (18)
EDSS, median (range) 1.5 (0–4) 1.5 (0–4.5) 1.5 (0–5)
Number of Gd-enhancing lesions 1.7 6 1.9 1.8 6 2.0 1.6 6 1.9
No. of patients with Gd-enhancing
lesions (%)
0 21 (42) 18 (36) 20 (41)
More than 0 29 (58) 32 (64) 29 (59)
1 8 13 13
2 6 3 4
3 2 2 3
‡4 13 14 9
Volume of T2-hyperintense lesions,
mm3, median (range)
6,514 (649–32,724) 5,933 (762–61,428) 5,655 (992–51,928)
Volume of T1-hypointense lesions,
mm3, median (range)
873 (0–9,964) 825 (0–15,501) 647 (0–15,435)
Abbreviations: EDSS 5 Expanded Disability Status Scale; Gd 5 gadolinium; IFN 5 interferon; OC 5 oral contraceptive.
The intention-to-treat population included all patients who underwent randomization and received at least 1 dose of IFN-b
treatment. None of the between-group comparisons were significant (nominal p . 0.05). All values are expressed as
mean 6 SD, unless otherwise indicated.
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these endpoints and found that treatment with high-
dose estrogens was not associated with reduction.
However, it must be emphasized that the
population studied was young women and very few
patients (.20%) showed a progression sustained for
6 months during the 2-year study. The combination
was well-tolerated and common AEs were generally
equally distributed across treatment groups.
As with other exploratory MS trials targeting
inflammatory processes, changes in MRI markers of
inflammation were selected as the first indication of
a potential therapeutic effect. MRI activity is as an
accepted surrogate outcome measure in proof-of-
concept clinical trials, and changes in CUA lesions
are the primary targets in relapse-onset MS studies.18
Several studies using the experimental autoim-
mune encephalomyelitis (EAE) model suggest an
anti-inflammatory effect of estradiol, providing
disease protection in several strains of mice.7 This
anti-inflammatory effect of estradiol is mediated by
nuclear estrogen receptor alpha and involves a
variety of mechanisms, including the induction of
CD41CD251 regulatory T cells and favorable
changes in autoantigen-specific cytokine production
in the peripheral immune system (i.e., decreased
tumor necrosis factor a, IFN-g, and interleukin
[IL]-6, with increased IL-5).19,20 It has been suggested
that the levels of estrogens in OC formulations are
not high enough to play an anti-inflammatory role in
MS. However, patients receiving OCs are less likely
to experience worsening of MS symptoms during the
menstrual cycle.21 Studies simulating treatment with
oral estradiol in EAE have shown a beneficial effect of
this hormone, suggesting that sustained levels of
estradiol are necessary to reduce disease activity.22,23
Progesterone, another component of OCs, also has
Table 2 Primary and secondary endpoints
Group 1
(n 5 50), IFN-b
Group 2 (n 5 50), IFN-b 1 OC
with low-dose estrogens
Group 3 (n 5 49), IFN-b 1 OC
with high-dose estrogens
p Value,
group 2 vs
group 1
p Value,
group 3 vs
group 1
Cumulative no. of CUA lesions at week 96
(95% CI); relative reduction, %
0.98 (0.81–1.14) 0.84 (0.66–1.02); 14.1 0.72 (0.53–0.91); 26.5 0.24a 0.04a
Cumulative no. of CUA lesions per patient
per scan at week 48 (95% CI); relative
reduction, %
0.39 (0.17–0.62) 0.42 (0.19–0.64); 25.8 0.33 (0.10–0.56); 16.0 0.88a 0.69a
No. of new Gd-enhancing lesions per patient
per scan at week 48 (95% CI); relative
reduction, %
0.22 (0.12–0.40) 0.21 (0.11–0.38); 7.4 0.08 (0.03–0.19); 65.4 0.83a 0.04a
No. of new Gd-enhancing lesions per patient
per scan at week 96 (95% CI); relative
reduction, %
0.24 (0.13–0.43) 0.11 (0.05–0.24); 52.4 0.11 (0.05–0.24); 54.2 0.07a 0.07a
Patients with no Gd-enhancing lesions at
week 48, n (%)
41 (82) 38 (76) 45 (92) 0.98b 0.11b
Patients with no Gd-enhancing lesions at
week 96, n (%)
37 (74) 39 (78) 45 (92) 0.17b 0.03b
Reduction of T2-hyperintense volume over
96 wk, mean 6 SD
3.99 6 20.48 10.30 6 34.40 6.48 6 19.78 0.43c 0.063a
Reduction of T1-hypointense volume over
96 wk, mean 6 SD
11.10 6 55.05 18.00 6 53.52 4.88 6 48.37 0.35c 0.98c
Annualized relapse rate from week 0 to
week 96, mean 6 SD
0.33 6 0.08 0.44 6 0.09 0.32 6 0.08 0.34d 0.97d
Patients relapse-free from week 0–96, n (%);
hazard ratio with group 1 (95% CI)
17 (34.0) 23 (46.0); 1.51 (0.81–2.85) 16 (32.7); 0.98 (0.49–1.94) 0.20e 0.95e
Patients relapse-free from week 0–48,
n (%); hazard ratio with group 1 (95% CI)
38 (76.0) 28 (56.0); 1.65 (0.80–3.41) 39 (79.6); 0.95 (0.42–2.16) 0.17f 0.90f
Patients relapse-free from week 48–96,
n (%); hazard ratio with group 1 (95% CI)
39 (78.0) 38 (76.0); 1.155 (0.49–2.68) 42 (85.7); 0.75 (0.30–1.875) 0.538f 0.738f
Patients with sustained disability progression
at week 96, n (%); hazard ratio with group
1 (95% CI)
3 (6) 6 (12); 1.36 (0.72–2.58) 4 (8); 0.97 (0.49–1.92) 0.348f 0.927f
Abbreviations: CI 5 confidence interval; CUA 5 combined unique active; EDSS 5 Expanded Disability Status Scale; Gd 5 gadolinium; IFN 5 interferon;
OC 5 oral contraceptive.
aCalculated using a Poisson regression model with adjustment for study group, age, number of Gd-enhancing lesions, and EDSS at baseline.
bCalculated using a logistic regression model with adjustment for study group and baseline number of Gd-enhancing lesions.
cCalculated using analysis of covariance on ranks with adjustment for study group.
dCalculated using negative binomial regression model with effect for study group and adjustment for age and number of relapses in the previous 2 years.
eCalculated using Cox proportional hazards model with adjustment for study group, age, and annualized relapse rate before study entry.
f Calculated using Cox proportional hazards model with adjustment for study group, age, and EDSS score at baseline.
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immunomodulatory effects. Although its beneficial
effect in EAE is controversial,7 its combination with
estradiol has been shown to influence disease activity
in MS.24,25 The ratio of progesterone to estradiol dur-
ing the luteal phase was significantly associated with
Gd-enhancing lesion burden.25
A dose effect of OCs was apparent in this study, as
reflected by a temporal delay of anti-inflammatory
action in the low estrogen group compared with the
high-dose group. OCs with high-dose estrogens sup-
pressed MRI activity in the first year, whereas OCs
with low-dose estrogens demonstrated a favorable
effect only in the second year of treatment (see
table 2). Studies on disease activity in rheumatoid
arthritis (RA) have provided further clues with respect
to which doses of estrogens are potentially protective
in MS. In a randomized placebo-controlled trial of
estradiol in RA, patients who achieved a serum estra-
diol level .100 pmol/L experienced significant im-
provements in symptoms and disease markers,
whereas those with lower levels of estradiol did
not.26 Together these reports suggest that estradiol
concentration and duration of exposure may exert
different effects on receptors or target immune cells,
with a varying degree of biological relevance. Safety
consideration limited the dose of estrogen contained
in the OC used in the present trial. Moreover, the 2
arms of OC treatment contained not only different
doses of estrogen but also slightly different doses of
progestrel; thus, the possibility of a combined effect
cannot be ruled out.
Whether OCs with high-dose estrogens enhance
the effect of IFN-b or IFN-b predisposes the
immune system to the beneficial effects of OCs re-
mains uncertain. The beneficial effect of high-dose
estrogens on MRI activity in this study could be
mediated by an inhibition of neutralizing antibodies
to IFN-b resulting from the immunomodulatory ef-
fects of estrogens. This hypothesis cannot be ruled
out since IFN-b–neutralizing antibodies were not
tested in the present study. On the other hand,
IFN-b treatment administered in combination with
hormone therapy may also modify the responsiveness
of hormone receptors for estrogen.27,28
Although high-dose estrogens in combination
with IFN-b show a beneficial effect, the risk–benefit
ratio of estrogen treatment requires some consider-
ation. OC treatment is a well-recognized risk factor
for vascular disorders. In this study, the rate of OC
treatment discontinuation due to AEs was similar in
the groups treated with high- and low-dose estrogens.
One patient treated with low-dose estrogens prema-
turely interrupted treatment because of an episode of
deep venous thrombosis. Although some evidence
suggests a possible increase in venous thromboembo-
lism with OCs containing .35 mg ethinylestradiol,
robust data to support this conclusion are lacking.29
The rate of IFN-b discontinuation was similar in
the OC-treated groups and the group treated with
IFN-b alone. The incidence of common IFN-b–
related AEs was also similar across the groups,
although flu-like symptoms appeared slightly less fre-
quently in the OC-treated groups. Whether OCs
played a role in attenuating the development of flu-
like symptoms through their immunomodulatory
properties remains unclear. However, this observa-
tion must be interpreted with caution since treating
physicians were not blinded to treatment arms.
Overall, the results of this study suggest that the
use of high-dose estrogens in combination with
IFN-b increases the anti-inflammatory effect of
IFN-b treatment in RRMS, possibly through additive
or synergistic effects, and it is well-tolerated by pa-
tients. Further studies will be necessary to prove a
sustained, clinically meaningful anti-inflammatory
effect of hormone-based therapy in MS. Extending
the investigations on the use of estrogen-based com-
pounds to aspects of tissue protection and repair will
allow their full potential to be realized in MS
treatment.
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